Printer Friendly

Articles from The Fly (May 29, 2020)

1-116 out of 116 article(s)
Title Author Type Words
AcelRx raises consideration to acquire Tetraphase. 225
Action Economics Survey results. 160
Adaptimmune presented updated data from its ADP-A2M4 Phase 1 trial at ASCO. 268
ADMA rises as 60 Minutes teases segment on 'Promise of Plasma'. 151
AgeX Therapeutics announces collaboration with Sernova. 292
Agios presents updated data from Phase 1 dose-escalation study of vorasidenib. 527
Akari Therapeutics pursuing clinical study opportunities in COVID-19 pneumonia. Clinical report 195
Akari Therapeutics says ongoing trials disrupted due to coronavirus spread. 258
Allogene Therapeutics reports results from Phase 1 ALPHA study of ALLO-501. Report 568
Amneal, four other drugmakers asked by FDA to recall lots of metformin ER. 165
Arvinas reports updated dose escalation data from trial of ARV-110. 708
Asian Market Update:. 244
AstraZeneca announces results from Imfinzi plus tremelimumab trial. 178
AstraZeneca reports results from updated CASPIAN trial analysis. 253
AstraZeneca says Enhertu improved overall survival in gastric cancer trial. 256
AstraZeneca says Imfinzi showed sustained overall survival benefit. 191
Atossa Therapeutics announces publication on SARS-CoV-2. 214
Aura Minerals expects to gradually resume activites at San Andres, Aranzazu. 308
Aura Minerals reports March, April consolidated net revenue $38.5M. Financial report 202
Autoliv says headcount reduced 'meaningfully' in April, more layoffs expected. 650
Autolus Therapeutics presents additional data on AUTO3 in DLBCL. 230
Aveo Pharmaceuticals DEDUCTIVE trial advances to Phase 2 portion. 205
Aveo presents results from final analysis of Phase 3 TIVO-3 trial. 291
BeiGene presents Phase 3 data on tislelizumab combined with chemotherapy. 619
BeiGene presents updated reslts from Phase 3 trial of zanubrutinib vs. ibrutinib. 816
Big Lots reports Q1 EPS $1.26 vs. 92c last year. Financial report 226
Big Lots sees Q2 EPS 65c-80c vs. 53c in Q2 of 2019. 207
Bio-Path Holdings presents trial design of its Phase 2 study of BP1001 at ASCO. 216
Blueprint Medicines presents data from ARROW clinical trial of pralsetinib. 198
BridgeBio's QED presents data on infigratinib in urothelial carcinoma, CCA. 284
Calithera Biosciences to present telaglenastat KEAPSAKE trial poster. 166
CannTrust: Health Canada says licenses for Fenwick facility reinstated. 170
Celsion DSMB recommends to proceed to Phase II of the Ovation 2 study. 175
Chondrial, Zafgen complete merger, begin operations as Larimar Therapeutics. 520
Circor reports Q1 adj. EPS 20c, consensus 45c. Financial report 288
Comcast, Charter, ViacomCBS announce Blockgraph partnership. 177
Comstock Holding reports Q1 EPS (0c) vs. 12c last year. Financial report 171
Corvus presents updated data from Phas 1b/2 trial of ciforadenant. 536
CytomX Therapeutics programs 'highlighted at ASCO20 virtual program. 237
Deciphera presents data from cohort of Part 2 of rebastinib Phase 1b/2 at ASCO. 204
Deciphera presents results from INVICTUS pivotal Phase 3 study at ASCO. 173
Defense Innovation Unit picks Zscaler for secure cloud management project. 224
DPW Holdings issues $200,000 convertible promissory note. 201
Duke Energy Florida announces 3 new solar power plants. 322
EnWave reports Q1 EPS C$0.02 vs. C$0.00 last year. Financial report 329
FDA approves Genentech's Tecentriq in combination with Avastin. 222
Fed Chair Powell repeated again that a negative rate strategy is not an appropriate tool. 229
Five Below says over 75% of stores reopened. 201
Fly Intel: Top five analyst downgrades. 184
Fly Intel: Top five analyst upgrades. 206
FX Action: USD-CAD has remained in a consolidation of recent losses. 247
FX Update: The yen has strengthened. 326
FX Update: The yen has strengthened. 321
Galera announces data from restrospective anaylsis of avasopasem manganese. 304
Genocea presents updated long-term data from GEN-009 Phase 1/2a trial. 335
Gilead announces results from interim analysis of ZUMA-5. Financial report 342
Gilead announces updated results from magrolimab trial. 305
GoPro achieves record camera unit sales over Memorial Day weekend. 184
Gossamer Bio announces presentation of KEYNOTE-A36 Phase 1/2 study data at ASCO. 276
Green Growth Brands announces extension of stay under insolvency proceedings. 211
Harpoon Therapeutics presents data from dosing trial for TriTAC HPN424 at ASCO. 261
Heat Biologics presents HS-110/Opdivo combination Phase 2 trial data at ASCO. 210
Humana awarded Medicaid contract from Kentucky CHFS. 230
Illinois American Water acquires City of Rosiclare wastewater system. 219
ImmunoGen announces initial data from FORWARD II study at ASCO. 276
IMV Inc. reports updated clinical response, data from DeCidE1 study. 320
Iovance presents data for TIL therapy lifileucel in advanced melanoma at ASCO. 241
Kite Realty Group launches Re-opening Resources program. 168
Kura reports data from tipifarnib study of metastatic HRAS mutant HNSCC. 311
Laurentian Bank reports Q2 adj. EPS C$0.20c vs. C$1.08 last year. Financial report 234
Ligand announces expansion of Icagen license agreement with Roche. 166
Lufthansa board accepts commitments offered by Germany to EU. 219
Mack-Cali 'strongly disagrees' with ISS and Glass Lewis recommendations. 154
Marimed expects significant revenue growth from Mass. operations through 2020. 311
Marimed intends to open fourth dispensary in Illinois later in 2020. 211
Marimed reports Q1 revenue $7.5M vs. $3.5M last year. Financial report 225
Marker Therapeutics reports results from MultiTAA-specific T cell therapy. Financial report 275
Menlo Therapeutics receives FDA approval of ZILXI topical foam. 315
Minerva says Phase 3 trial of roluperidone did not meet primary endpoint. 347
Moderna says first patients dosed in Phase 2 study of mRNA COVID-19 vaccine. 158
Myovant Sciences announces additional data from Phase 3 HERO study. 511
Myriad Genetics presents new data on riskScore test. 325
Nabriva gets 'positive' EU CHMP opinion for Xenleta for CAP treatment. 213
Northern Dynasty subsidiary Pebble issues statement regarding mine project. 452
NovaGold calls short seller report 'misleading', 'inaccurate'. 359
OraSure to acquire UrSure for cash. 480
Pacific Ethanol appoints Mike Kandris as co-president, co-CEO. 176
PTAB rules in favor of Mylan, invalidating Sanofi Lantus SoloSTAR patents. 193
Rapt Therapeutics announces poster presentation for Phase 1/2 trial of FLX475. 288
Regeneron, Sanofi present longer-term data for PD-1 inhibitor Libtayo. 201
Renault to slash nearly 15,000 jobs worldwide under transformation plan. 356
Sanofi announces presentation of Libtayo longer-term results in CSCC. 403
Seattle Genetics announces results from exploratory analyses of HER2CLIMB trial. Financial report 232
Sony announces PlayStation 5 event for June 4. 336
Syros Pharmaceuticals presents new preclinical data for SY-5609 at ASCO. 192
Tetraphase announces second amendment to merger agreement with AcelRx. 650
TG Therapeutics announces final results of GENUINE Phase 3 study. Clinical report 290
The advance indicators report. 273
The downward revision in May Michigan sentiment reading. 279
The U.S. personal income report sharply beat estimates. 260
Thor Industries announces operational update with start of RV travel season. 343
TPG RE Finance announces strategic investment from Starwood Capital. 303
Tracon highlights updated Envafolimab results in MSI-H/dMMR colorectal cancer. Clinical report 225
Treasury Market Outlook: risk appetite continues to fade. 162
Treasury Market Summary. 220
Trillium updates dose escalation sudy of CD47 Blocker TTI-622 at ASCO. 226
Trump order may put 'overhang' on big tech in coming months, says JPMorgan. 153
Turning Point presents data for novel RET inhibitor candidate, TPX-0046. 348
Twitter says Trump 'THUGS' tweet violates glorification of violence policy. 167
Tyson says 326 of 1,604 team members tested positive for COVID at Texas plant. 181
U.S. equity futures are mostly weaker. 168
U.S. personal income surged 10.5% in April while consumption dove -13.6%. 182
Vir Biotechnology, Biogen enter agreement to manufacture SARS-CoV-2 antibodies. 215
Volkswagen intensifies e-mobility activities in China. 239
Wells Fargo names Kevin Reen CRO for consumer lending. 206
Ziopharm presents data for controlled IL-12 for rGBM at ASCO. 354

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters